Safety and immunogenicity of vaccines against SARS-CoV-2

Q4 Medicine

Archivos Venezolanos de Farmacologia y Terapeutica Pub Date : 2021-01-01 DOI:10.5281/zenodo.5839028

F. Paredes, E. Enriquez, M. A. N. Peralvo

{"title":"Safety and immunogenicity of vaccines against SARS-CoV-2","authors":"F. Paredes, E. Enriquez, M. A. N. Peralvo","doi":"10.5281/zenodo.5839028","DOIUrl":null,"url":null,"abstract":"The mortality rate estimated by the WHO worldwide for CO-VID-19 has been 5.7%, much higher than other communicable infectious diseases, so it is essential to apply a vaccine to the population to reduce the viral spread, according to the WHO there are 23 projects in clinical phase stage III, such as vaccines: ChadOx1, nCov-19, Gam-COVID-Vac, CoronaVac that show promising results in research published by The Lancet Infection Diseases journal, for which we consider correlating the three vaccines and determining which is safer, generates greater im-munogenicity and less reactogenicity in volunteer participants, for which we conducted a review bibliography and a meta-anal-ysis of high impact scientific articles, concluding that the three vaccines generate a rapid and intense immune response against SARS-CoV-2, neutralizing antibodies had elevated titers in participants at 28 days, who increased and remained stable with a second dose, although each of them have been tested in different numbers and populations, applying recombinant adenovi-ral vectors and chemically inactivated virions with adjuvant and placebo for which they are totally different but with the same purpose to generate memory antibodies against SARS-CoV-2. Copyright © 2021, Venezuelan Society of Pharmacology and Clinical and Therapeutic Pharmacology. All rights reserved.","PeriodicalId":34888,"journal":{"name":"Archivos Venezolanos de Farmacologia y Terapeutica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos Venezolanos de Farmacologia y Terapeutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.5839028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

The mortality rate estimated by the WHO worldwide for CO-VID-19 has been 5.7%, much higher than other communicable infectious diseases, so it is essential to apply a vaccine to the population to reduce the viral spread, according to the WHO there are 23 projects in clinical phase stage III, such as vaccines: ChadOx1, nCov-19, Gam-COVID-Vac, CoronaVac that show promising results in research published by The Lancet Infection Diseases journal, for which we consider correlating the three vaccines and determining which is safer, generates greater im-munogenicity and less reactogenicity in volunteer participants, for which we conducted a review bibliography and a meta-anal-ysis of high impact scientific articles, concluding that the three vaccines generate a rapid and intense immune response against SARS-CoV-2, neutralizing antibodies had elevated titers in participants at 28 days, who increased and remained stable with a second dose, although each of them have been tested in different numbers and populations, applying recombinant adenovi-ral vectors and chemically inactivated virions with adjuvant and placebo for which they are totally different but with the same purpose to generate memory antibodies against SARS-CoV-2. Copyright © 2021, Venezuelan Society of Pharmacology and Clinical and Therapeutic Pharmacology. All rights reserved.

查看原文本刊更多论文

SARS-CoV-2疫苗的安全性和免疫原性

据世界卫生组织估计，covid -19在全球范围内的死亡率为5.7%，远高于其他传染性疾病，因此必须向人群接种疫苗，以减少病毒的传播。据世界卫生组织称，目前有23个项目处于疫苗等临床第三阶段。ChadOx1、nCov-19、Gam-COVID-Vac、CoronaVac在《柳叶刀传染病》杂志发表的研究中显示出有希望的结果，我们认为这三种疫苗之间存在关联，并确定哪一种更安全，在志愿者参与者中产生更大的免疫原性和更少的反应原性，为此我们对高影响力科学文章进行了综述书目和荟荟性分析。结论是，这三种疫苗对SARS-CoV-2产生了快速而强烈的免疫反应，中和抗体在28天的参与者中滴度升高，在第二剂后滴度增加并保持稳定，尽管每种疫苗都在不同的数量和人群中进行了测试，将重组腺病毒载体和化学灭活病毒粒子与佐剂和安慰剂结合使用，它们完全不同，但目的相同，以产生针对SARS-CoV-2的记忆抗体。版权所有©2021，委内瑞拉药理学和临床与治疗药理学学会。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos Venezolanos de Farmacologia y Terapeutica Medicine-Pharmacology (medical)

自引率

0.00%

发文量

期刊介绍： La revista AVFT es una publicación biomédica periódica, arbitrada, de aparición trimestral, destinada a promover la productividad científica de la comunidad nacional e internacional en todas las áreas de Ciencias de la Salud y Educación en Salud; la divulgación de artículos científicos y tecnológicos originales y artículos de revisión por invitación del Cómité Editorial. Está basada en un Comité de Redacción, consistente en un Editor-Director, Editores asociados principales y Comisión Editorial y Redactora. Los manuscritos que publica pueden ser de autores nacionales o extranjeros, residentes o no en Venezuela, en castellano (con resumen en idioma inglés y castellano) y deben ser remitidos a la Redacción de la Revista.